Market Overview

Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Directors


Aradigm Corporation (NASDAQ:ARDM) (the "Company") today
announced the appointment of Dr. Theresa Matkovits to the Board, the
Audit Committee of the Board and the Nominating and Corporate Governance
Committee of the Board.

Dr. Matkovits is Chief Operating Officer of ContraVir Pharmaceuticals
("ContraVir"). Dr. Matkovits has served as ContraVir's Chief Operating
Officer since December 2017, previous to which, she served as Executive
Vice President, Head of Drug Development at ContraVir from May 2015 to
November 2017. From March 2013 to May 2015, Dr. Matkovits was the
Research and Development Program Leader at NPS Pharmaceuticals ("NPS"),
where she led the integration of two commercial assets acquired from
Takeda into NPS and led NPS's global development efforts for Natpara.
From 2010 to February 2013, Dr. Matkovits was Vice President, Innovation
Leader for Infectious Disease at The Medicines Company, where she led
the company's development efforts for ORBACTIVE. From 1997 to 2010, Dr.
Matkovits served in various roles including Executive Director, Head of
Strategic Planning and Operations for Novartis, where she fulfilled
leadership roles in global development and U.S. Medical Affairs for the
company's general medicine portfolio. From 2017 to present, Dr.
Matkovits has served as a Board Director of BioSurplus.

Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology
from the University of Medicine and Dentistry of New Jersey and
completed her undergraduate studies at Alfred University.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm has completed two
Phase 3 trials with Linhaliq, an investigational proprietary formulation
of ciprofloxacin for inhalation for the treatment of non-cystic fibrosis
BE and submitted an NDA to the FDA for this indication. Aradigm's
inhaled ciprofloxacin formulations include Linhaliq and Lipoquin which
are also product candidates for treatment of patients with cystic
fibrosis and non-tuberculous mycobacteria, and for the prevention and
treatment of high threat and bioterrorism infections, such as inhaled
tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

More information about Aradigm can be found at

About Non-Cystic Fibrosis Bronchiectasis

NCFBE is a severe, chronic and rare disease characterized by abnormal
dilatation of the bronchi and bronchioles, frequently associated with
chronic lung infections. It is often a consequence of a vicious cycle of
inflammation, recurrent lung infections, and bronchial wall damage.
NCFBE represents an unmet medical need with high morbidity and mortality
that affects more than 150,000 people in the U.S. and over 200,000
people in Europe. There is currently no drug approved for the treatment
of this condition. NCFBE patients who have chronic infections with P.
have a 6.5-fold increase in hospitalization, three times
higher mortality, and a worse quality of life compared with those
without P. aeruginosa infections.

Forward-Looking Statements

Except for the historical information contained herein, this news
release contains forward-looking statements that involve risk and
uncertainties, including the risk that Linhaliq may not receive
regulatory approval or be successfully commercialized, as well as the
other risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission (SEC), including the Company's Annual
Report on Form 10-K for the year ended December 31, 2017 filed with the
SEC on March 23, 2018, and the Company's Quarterly Reports on Form 10-Q.

Aradigm, Pulmaquin and the Aradigm Logo are registered trademarks of
Aradigm Corporation. Linhaliq is a registered trademark of Grifols, S.A.

View source version on

View Comments and Join the Discussion!